Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Levels and Its Association with Renal Allograft Rejection

References

• Ajuebor MN, Flower RJ, Hannon R, et al. 1998. Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model. J Leukoc Biol 63(1):108–116. PMID: 9469480.
   PubMed Web of Science ®Google Scholar
• Ansari AW, Schmidt RE, Shankar EM, Kamarulzaman A. 2014. Immuno-pathomechanism of liver fibrosis: Targeting chemokine CCL2-mediated HIV:HCV nexus. J Transl Med 12:341. PMID: 25528160.
   Web of Science ®Google Scholar
• Boratyńska M. 1998.The role of monocyte chemotactic peptide (MCP-1) in chronic renal allograft rejection. Pol Arch Med Wewn 99(4):272–280. PMID: 9760814.
   PubMedGoogle Scholar
• De Serres SA, Mfarrej BG, Grafals M, et al. 2012. Derivation and validation of a cytokine-based assay to screen for acute rejection in renal transplant recipients. Clin J Am Soc Nephrol 7(6):1018–1025. PMID: 22498498.
   PubMed Web of Science ®Google Scholar
• Dubiński B, Boratyńska M, Kopeć W, et al. 2008. Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1)–sensitive rejection markers in renal graft recipients. Transpl Immunol 18(3):203–207. PMID:18047927.
   PubMed Web of Science ®Google Scholar
• Grandaliano G, Gesualdo L, Ranieri E, et al. 1997. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Transplantation 6(3):414–420. PMID: 9039933.
   Web of Science ®Google Scholar
• Gu L, Tseng SC, Rollins BJ. 1999. Monocyte chemoattractant protein-1. Chem Immunol 72:7–29. PMID: 10550927
   Google Scholar
• Hirt-Minkowski P, Amico P, Ho J, et al. 2012. Detection of clinical and subclinical tubule-interstitial inflammation by the urinary CXCL10 chemokine in a real-life setting. Am J Transplant 12:1811–1823.
   PubMed Web of Science ®Google Scholar
• Hirt-Minkowski P, De Serres SA, Ho J. 2015. Developing renal allograft surveillance strategies-urinary biomarkers for cellular rejection. Can J Kidney Health and Dis 2:28. doi: 10.1186/s40697-015-0061-x. PMID: 26285614
   Google Scholar
• Ho J, Rush DN, Gibson IW, et al. 2010. Early urinary CCL2 is associated with the laterdevelopment of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 90(4):394–400. PMID: 20625355
   PubMed Web of Science ®Google Scholar
• Ho J, Wiebe C, Rush DN, et al. 2013. Increased urinary CCL2: Cr ratio at 6 months is associated with late renal allograft loss. Transplantation 95(4):595–602. PMID: 23192155.
   PubMed Web of Science ®Google Scholar
• Jackson JA, Kim EJ, Begley B, et al. 2011. Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection. A J Transplant 11:2228–2234.
   PubMed Web of Science ®Google Scholar
• Kazi JI, Mubarak M. 2012. Biopsy Findings in Renal Allograft Dysfunction in a Live Related Renal Transplant Program. J Transplant Technol Res 2:108.
   Google Scholar
• Kitagawa K, Wada T, Furuichi K, et al. 2004. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 165(1):237–246. PMID: 15215179.
   PubMed Web of Science ®Google Scholar
• Prodjosudjadi W, Daha MR, Gerritsma JS, et al. 1996. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 11(6):1096–1103. PMID: 8671975.
   PubMed Web of Science ®Google Scholar
• Racusen LC, Solez K, Colvin RB, et al. 1999. The Banff 97 working classification of renal allograft pathology.Kidney Int 55(2):713–723. PMID: 9987096.
   Google Scholar
• Rice JC, Spence JS, Yetman DL, Safirstein RL. 2002. Monocyte chemoattractant protein-1 expression correlates with monocyte infiltration in the post-ischemic kidney. Ren Fail 24(6):703–723. PMID: 12472194.
   PubMed Web of Science ®Google Scholar
• Robertson H, Morley AR, Talbot D, et al. 2000. Renal allograft rejection: Beta-chemokine involvement in the development of tubulitis. Transplantation 69(4):684–687. PMID: 10708134.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Doe N, Tan LC. 1996. Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am. J Kidney Dis 27(5):640–646. PMID: 8629622.
   PubMed Web of Science ®Google Scholar
• Rüster M, Sperschneider H, Fünfstück R, et al. 2004. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol 61(1):30–39. PMID:14964455.
   PubMed Web of Science ®Google Scholar
• Schaub S, Nickerson P, Rush D, et al. 2009. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 9:1347–1353.
   PubMed Web of Science ®Google Scholar
• Segerer S, Cui Y, Eitner F, et al. 2001. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am. J Kidney Dis 37(3):518–531. PMID:11228176.
   PubMed Web of Science ®Google Scholar
• Sun XH, Tan JM, Wu WZ, et al. 2003. Significance of detecting urinary monocyte chemotactic peptide-1 in renal transplant recipient. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19(6):563–564. PMID: 15182651.
   PubMedGoogle Scholar
• Suthanthiran M, Schwartz JE, Ding R, et al. 2013. Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. New Eng J Med 369:20–31.
   PubMed Web of Science ®Google Scholar
• Tam FW, Sanders JS, George A, et al. 2004. Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol Dial Transplant 19(11):2761–2768. PMID: 15353578.
   PubMed Web of Science ®Google Scholar
• Tullius SG, Tran H, Guleria I, et al. 2010. The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome. Ann Surg 252(4):662–674.
   PubMed Web of Science ®Google Scholar
• Van Coillie E, Van Damme J, Opdenakker G. 1999. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 10(1):61–86. PMID:10379912.
   PubMed Web of Science ®Google Scholar
• Van Ham SM, Heutinck KM, Jorritsma T, et al. 2010. Urinary granzyme A mRNA is a biomarker to diagnose subclinical and acute cellular rejection in kidney transplant recipients. Kidney Int 78:1033–1040.
   PubMed Web of Science ®Google Scholar
• Varma PP, Hooda AK, Sinha T, et al. 2007. Renal Transplantation – An Experience of 500 Patients. MJAFI; 63: 107–111.
   Google Scholar
• Wada T, Furuichi K, Segawa-Takaeda C, et al. 1999. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56(3):995–1003. PMID: 10469367.
   PubMed Web of Science ®Google Scholar